Trials / Available
AvailableNCT04960891
A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp
A Cohort IND Expanded Access Program (EAP) for Tebentafusp for Treatment of HLA-A*02:01 Positive Patients With Metastatic Uveal Melanoma
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Immunocore Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This Expanded Access Program aims to: 1. Provide access to tebentafusp for mUM patients. 2. Provide access to tebentafusp for patients, who were on the control arm of the randomized controlled Phase II trial (IMCgp100-202) and were unable to crossover during the specified window. 3. Ensure that patients, who are benefiting from tebentafusp treatment while participating in an ongoing Immunocore sponsored clinical study (e.g., IMCgp100-102 or IMCgp100-201), may continue tebentafusp treatment on this Programme once the ongoing trial has met all of its key primary and secondary objectives.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tebentafusp | Concentrate solution for intravenous infusion |
Timeline
- First posted
- 2021-07-14
- Last updated
- 2022-01-21
Source: ClinicalTrials.gov record NCT04960891. Inclusion in this directory is not an endorsement.